According to CNBC, shares of Wegovy-maker Novo Nordisk rose 6% after approval of a GLP-1 pill, signaling a strong positive price reaction to the regulatory catalyst, source: CNBC. CNBC did not provide additional details in the tweet or any direct implications for the crypto market, source: CNBC.

According to @StockMKTNewz, the US FDA approved the first-ever GLP-1 pill for weight loss from Wegovy maker Novo Nordisk (NVO), as reported by CNBC. This establishes the first oral GLP-1 option for obesity treatment and marks a major regulatory catalyst for NVO, per @StockMKTNewz citing CNBC. The source post did not provide label details, pricing, launch timing, or market reaction data, and it did not mention any cryptocurrency impacts, according to @StockMKTNewz.

According to @CNBC, Eli Lilly's next-generation obesity drug retatrutide delivered strong weight loss and reduced knee pain in a late-stage trial. Source: CNBC. The report highlights efficacy signals for retatrutide in a late-stage setting, indicating notable clinical progress within Eli Lilly's obesity pipeline. Source: CNBC. The post did not provide details on LLY share price reaction, regulatory timelines, or implications for BTC, ETH, or broader crypto markets. Source: CNBC.